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Ab s t r a c t
Introduction: This meta-analysis compares the effectiveness and safety of tumor
necrosis factor α (TNF-α) antibodies (infliximab, adalimumab and certolizumab)
with either a placebo or each of them in the treatment of Crohn’s disease (CD).
Material and methods: A systematic review of literature published up to Novem-
ber 2012 was performed and a meta-analysis of identified studies was carried
out. We searched the following databases: PubMed, EMBASE, The Cochrane
Library and others. Only randomized or clinical controlled trials were included.
Results: Nineteen clinical trials fulfilled the established criteria (5 studies for
infliximab vs. placebo, 6 for each adalimumab or certolizumab vs. placebo and
2 comparing infliximab with adalimumab). The results of meta-analysis showed
that anti-TNF therapy in patients with CD is safe and statistically significantly
more effective when compared with the placebo for induction of remission at
week 4 (RB = 1.90, 95% CI: 1.55–2.33, p < 0.00001), maintenance of remission
at weeks 20–30 (RB = 1.86, 95% CI: 1.61–2.15, p < 0.00001) and at weeks 48–56
(RB = 2.75, 95% CI: 2.13–3.54, p < 0.00001) in patients who responded to the
induction therapy and patients randomized before the induction. Anti-TNF agents
were also superior to the placebo in fistula healing (during short-term induc-
tion, as well as long-term maintenance) and inducing CR-70 but not CR-100 at
week 4. Moreover, the anti-TNF therapy had a significant effect on achieving
both CR-70 and CR-100 during long-term maintenance.
Conclusions: Infliximab, adalimumab and certolizumab are effective as both
induction and maintenance therapy in moderate to severe Crohn’s disease in
adults, including patients with fistulas. The safety profile was acceptable.
Key words: Crohn’s disease, tumor necrosis factor-α antibodies, systematic review,
meta-analysis.
Introduction
Crohn’s disease (CD) is a chronic and disabling inflammatory disease
of the digestive tract of unknown etiology. It may affect any part of the
gastrointestinal tract from the mouth to the anus, but most commonly
the terminal ileum or the ileocecal region is affected. The highest incidence
of ulcerative colitis and CD has been reported in: Northern Europe, the
United Kingdom and North America [1]. The etiology of CD remains un -
known, but the characteristic disproportionate inflammatory response 
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in the gut may develop through various mecha-
nisms at the cellular and subcellular level [1]. Cur-
rent medical treatment of CD, besides convention-
al therapy such as sulfasalazine, 5-aminosalicylates,
corticosteroids and immunomodulators, include bio-
logical therapy [2]. Tumor necrosis factor (TNF) α is
a crucial mediator of the abnormal immune res -
ponse in the gut and in recent years, biological ther-
apies targeting TNF-α have significantly improved
the management of CD refractory to conventional
therapies [3]. Infliximab, adalimumab and certo -
lizumab pegol are anti-TNF-α antibodies approved
for the treatment of CD. 
The aim of this systematic review with meta-
analysis was to assess the effectiveness and safe-
ty of infliximab, adalimumab and certolizumab
when compared with placebo (or each other) for
induction and maintenance treatment, as well as
fistula closure in adults with Crohn’s disease.
Material and methods
This meta-analysis included all parallel random-
ized or clinical controlled trials (CCTs) comparing
infliximab, adalimumab or certolizumab in any
dosage/treatment regimen with placebo or each
other. The studies included had to be performed
with a control group but not necessarily with ran-
dom allocation and/or blinding. Articles published
as a full text were preferable because of the oppor-
tunity to verify the reliability or potential useful-
ness of the studies (availability of the full text of
primary studies allows an accurate assessment of
their quality and also provides essential informa-
tion about the study population, applied treatment
regimen and specific data to extract), but unpub-
lished ones were also taken into consideration. The
participants in these studies were adults (≥ 18 years
old) with moderate to severe, as well as fistulizing,
active CD. Studies concerning combination therapy
in comparison with monotherapy or surgical inter-
vention, or comparing different dosage/treatment
regimens of the same drug, were excluded. 
In order to find the primary studies, the follow-
ing electronic databases were searched up to
November 2012: MEDLINE via PubMed, EMBASE
and the Cochrane Central Register of Controlled Tri-
als. Searches for primary studies were also restrict-
ed and based on appropriate MeSH and EMTREE
terms that meet the requirements: Crohn’s disease
and the intervention infliximab, adalimumab or cer-
tolizumab, combined with Boole's logical operators
(Table I). The Cochrane Database of Systematic
Reviews, DARE, PubMed and EMBASE databases
were also searched for review articles. In addition,
the Cochrane IBD/FBD Review Group Specialized
Trials Register and websites of the British Society
of Gastroenterology and European Crohn’s and 
Colitis Organization were searched for relevant
information concerning the clinical trials. Regis-
ters of controlled trials (www.clinicaltrials.gov) 
were searched for unpublished or ongoing trials.
Reference lists from potentially relevant papers
were hand-searched in order to identify additional
studies.
The methods of the systematic reviews were
applied as described in the Cochrane Handbook [4],
and the report was prepared according to the pre-
ferred reporting items for systematic reviews and
meta-analyses (PRISMA) guidelines [5]. The search
and selection of the trials that were included were
conducted by two reviewers independently. All of
the potentially relevant articles were retained and
their full text was critically reviewed according to
the predefined inclusion or exclusion criteria. Data
extraction was performed by a single reviewer using
a standard data extraction form, before being
then checked by a second reviewer. For the includ-
ed studies, information was extracted on study
design, severity of disease, dosage and scheme of
Key words (combined with Boole's logical operator, OR)
Medical condition Crohn disease OR Crohn's disease OR Crohns disease OR Ileocolitis OR Ileitis, Terminal OR Ileitis, 
regional OR Colitis, granulomatous OR Enteritis, granulomatous OR Enteritis, regional OR Enteritis 
regionalis OR Regional enterocolitis OR Morbus Crohn OR Cleron disease
Intervention Infliximab OR Remicade OR Revellex OR Avakine OR Monoclonal antibody cA2 OR MAb cA2 OR 
Schering-Plough brand of infliximab OR Schering brand of infliximab OR Centocor brand 
of infliximab OR Essex brand of infliximab
Adalimumab OR Humira OR trudexa OR D2E7 antibody OR Abbott brand of adalimumab
Certolizumab OR Cimzia OR CDP870 OR CDP 870 OR UCB Pharma brand of certolizumab pegol OR 
Pegylated tumor necrosis factor alpha antibody Fab fragment OR pha 738144 OR pha738144
Methodological PubMed: Humans, Randomized Controlled Trial, Clinical Trials, Controlled Clinical Trial
limits EMBASE: Humans, Controlled Clinical Trials, Randomized Controlled Trial, Embase only
CENTRAL: No limits applied; word variations have been searched
Language limits PubMed, EMBASE: English, French, German, Polish
Table I. MeSH subject headings and EMTREE keywords used in constructed search strategy for primary studies (last
updated: 22.11.2012)
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the administered anti-TNF-α agents, duration of
treatment and clinical outcomes. The methodolog-
ical quality of each of the trials included was
assessed independently by two reviewers. Ran-
domized clinical trials (RCTs) included in the pres-
ent review were evaluated using the Jadad scale [6],
and the CCT was assessed using the Newcastle-
Ottawa Scale (NOS) [7]. 
The outcome measures reported in the selected
studies were based mainly on changes in the
Crohn’s Disease Activity Index (CDAI) and included:
clinical response defined as a reduction of ≥ 70
points (CR-70) or of ≥ 100 points (CR-100) from the
baseline in the CDAI score, and clinical remission
defined as a decrease in the CDAI score of ≤ 150
points from baseline. Safety profile was also as -
sessed.
Statistical analysis
For dichotomous data, the impact of the inter-
vention was expressed as a relative benefit – RB
(described as risk ratio (RR) on the graphs present-
ed due to specific labeling of the effect measure-
ment in the statistical analysis software) with 95%
confidence intervals (CI). Adverse events were sum-
marized with RR (relative risk). The results obtained
from separate trials were combined using appro-
priate meta-analysis methods. The inverse variance,
Mantel-Haenszel or Der Simonian-Laird effects
model was used according to the data input and
heterogeneity test results. The results were pooled
for sufficiently similar outcomes and homogeneous
data (determined by the degree of clinical and sta-
tistical heterogeneity). The clinical heterogeneity
was assessed by examining the characteristics of
the featured studies, whereas the statistical het-
erogeneity was assessed using the χ2 test, with the
significance regarded as a p value =0.10. Relative
parameters were calculated using a fixed effects
model when the statistical heterogeneity was not
detected, and a random effects model was used
when heterogeneity was present. In all of the analy-
ses RevMan 5.1.0 was used.
Results
Systematic review
The initial search identified 1072 citations, 1025
of which were excluded after examining the titles
and abstracts. A further performed selection result-
ed in the identification of 47 potentially eligible
studies. A total of 28 articles were excluded for var-
ious reasons, and 18 RCTs and 1 CCT fulfilled the
inclusion criteria (Figure 1). In addition, 45 ongoing
trials of infliximab, adalimumab or certolizumab
were identified at www.clinicaltrials.gov, although
they did not meet the inclusion criteria.
The studies included two trial designs: induction
therapy and maintenance therapy, in both popula-
tions of adult patients: moderate to severe, pre-
dominantly or wholly non-fistulizing CD and fis-
tulizing disease. All the studies were published in
English as peer-reviewed articles. Among the five
included randomized controlled trials comparing
infliximab with placebo, 3 RCTs were conducted in
Duplicates removed: 51
Excluded because title and abstract revealed 
not appropriate: 1025
Potentially relevant papers and screened for retrieval: 1072
Studies retrieved for evaluation based on full-text paper: 47
Results of hand searching of references lists: 1
Studies included and used for meta-analysis: RCTs; 18, CCT
Excluded after reviewing full-text (n = 28)
because:
– no placebo in control group: 2
– secondary publication of an included
study (not the outcome of interest,
uncontrolled subgroup analyses): 12
– comparison of different dosages of the
same anti-TNF agent: 4
– comparison with combination treatment
of surgical intervention: 8
– treatment post surgical resection: 2
Figure 1. PRISMA flow diagram for selection of studies identified in the systematic review
Total number of hits in main databases: 966
(PubMed – 294; Embase – 550; Cochrane –122)
Total number of hits in additional sources 
(websites, register of clinical trials): 157
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patients with non-fistulizing Crohn’s disease for
induction treatment. The characteristics and the
methodological quality of the trials included are
described in Table II.
Each of the studies included had a parallel group
design and almost all of the RCTs were conducted
with double blinding. A majority of the randomized
studies scored ≥ 3 points on the Jadad scale, indi-
cating good methodological quality, except for study
[26] which scored two points due to its open-label
design, and studies [18, 22] due to a lack of descrip-
tion of withdrawals and dropouts. Six of the stud-
ies did not provide information on allocation con-
cealment (Table III).
Efficacy analysis
We performed a meta-analysis of eligible RCTs
that compared infliximab, adalimumab and cer-
tolizumab (separately as subgroups and then to -
gether) with a placebo. In particular comparisons,
combined doses of anti-TNF agents were used. The
efficacy endpoints were: clinical remission at week
4 for short- and one long-term induction trials and
separately at weeks 20–30, for studies evaluating
the maintenance of remission after an open-label
induction (primarily among responders) at weeks
48–56. Week 4 was chosen because in most of the
induction studies the results were shown for that
period, and because the placebo response and
remission rates increased after 4 weeks in the
induction studies [8]. An evaluation of the clinical
response (CR-70 or CR-100) was performed sepa-
rately for both short- and long-term induction stud-
ies (with the data extracted at week 4) and for long-
term maintenance studies (48–56 weeks, one study
[24] lasted only 26 weeks). For the fistulizing form
of CD, the efficacy endpoints were closure of ≥ 50%
of draining fistulas and complete fistula closure
after ≥ 2 consecutive visits.
Induction of remission at week 4
Eight trials assessing the efficacy of the three
anti-TNF agents for short-term induction of remis-
sion were included: seven short-term trials [9, 14,
15, 19–22] and one long-term induction trial [23].
We included the Winter et al. 2004 [20] study,
although certolizumab was administered not sub-
cutaneously but intravenously. Finally, it turned out
Study The Jadad scores Allocation 
1 2 3 4 5 Total Jadad
concealment
[9] Targan 1997 1 0 1 1 1 4 Yes
[10] Rutgeerts 1999 1 0 1 0 1 3 Yes
[11] Hanauer 2002 1 0 1 0 1 3 Yes
[12] Sands 2004 1 0 1 0 1 3 Unclear
[13] Present 1999 1 0 1 1 1 4 Yes
[14] Hanauer 2006 1 0 1 0 1 3 Yes
[15] Sandborn 2007 1 0 1 0 1 3 Yes
[16] Sandborn 2007 1 0 1 0 1 3 Yes
[17] Colombel 2007 1 0 1 0 1 3 Yes
[18] Rutgeerts 2012 1 0 1 0 0 2 Unclear
[19] Watanabe 2012 1 0 1 0 1 3 Unclear
[20] Winter 2004 1 0 1 0 1 3 Unclear
[21] Schreiber 2005 1 0 1 0 1 3 Unclear
[22] Sandborn 2011 1 0 1 0 0 2 Unclear
[23] Sandborn 2007 1 0 1 0 1 3 Yes
[24] Schreiber 2007, 1 0 1 0 1 3 Yes
[25] Schreiber 2011
[26] Van Assche 2012 1 0 0 0 1 2 Yes
Study The NOS score
[27] Riis 2012 Good quality
Table II. Methodological quality of included RCTs and CCT
1 – Was the study described as randomized?; 2 – Was the method of randomization described and appropriate?; 3 – Was the study described as
double blind?; 4 – Was the method of blinding described and appropriate?; 5 – Were withdrawals and dropouts described? Additional explana-
tion: question 2 has been scored 0 in case of lack of any description or when the method of randomization used in the study was other than
simple; question 4 has been scored 0 in case of lack of any description of blinding or when the presented description was not detailed
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Study author 
and year 
of publication;
design; sites
Population;
severity of CD
N (for efficacy) Dosage and schedule, duration 
of treatment and follow-up
Outcomes and
point at which
extracted
Infliximab vs. placebo
[9] Targan
1997; RCT; 
18 sites
Moderate-to-
severe Crohn’s
disease
Placebo, n = 25; 
infliximab 5 mg, 
n = 27; 10 mg, n = 28;
20 mg, n = 28
Induction:
placebo or infliximab 5 mg/kg; 10 mg/kg,
or 20 mg/kg at week 0 (to week 12)
Remission: 
CDAI < 150 at
weeks 4 and 12
[10] Rutgeerts
1999; RCT; 
17 sites
Crohn’s disease
and clinical
response to ini-
tial treatment
in previous
study [9]
Placebo, n = 36; 
infliximab, n = 27
Maintenance:
initial response to placebo or infliximab
(Targan), then at week 12 randomiza-
tion to placebo or infliximab 10 mg/kg, 
at 8-weekly intervals thereafter 
(to week 48)
Remission: 
CDAI ≤ 150 
at week 48
[11] Hanauer
2002, 
ACCENT I; 
RCT; 55 sites
Moderate-to-
severe Crohn’s
disease
Randomized as respon-
ders at week 2: placebo,
n = 110; infliximab 5 mg,
n = 113; 
infliximab 5 and 10 mg, 
n = 112
Maintenance:
initial response to open-label infliximab
5 mg/kg, then randomization to placebo
or infliximab 5 mg/kg at weeks 2 and 
6 or infliximab 5 mg/kg at weeks 2 and
6 followed by 10 mg/kg at 8-weekly
intervals thereafter (to week 46).
Note: both infliximab groups received 
5 mg/kg at weeks 2 and 6
Remission: 
CDAI ≤ 150 
at week 54 
(for ‘2-week’
responders)
[12] Sands
2004, 
ACCENT II,
RCT; 45 sites
Crohn’s disease
and ≥ 1 drain-
ing abdominal
or perianal fis-
tulas of 
≥ 3 months’
duration
Randomized respon-
ders, n = 195: placebo, 
n = 99; infliximab, 
n = 96
Maintenance:
infliximab 5 mg/kg at weeks 0, 2 and 
6 for all patients; at week 14 responders
(n = 195) and non-responders (n = 87)
were randomized to placebo or inflix-
imab 5 mg/kg at 8-weekly intervals
thereafter (to week 54)
Absence of any
draining fistulas
or reduction ≥ 50%
in the number of
draining fistulas
at week 54 (for
responders)
[13] Present
1999; RCT; 
12 sites
Crohn’s disease
and draining
abdominal or
perianal fistulas
of ≥ 3 months’
duration
Placebo, n = 31; 
infliximab 5 mg, n = 31; 
10 mg, n = 32
Induction:
placebo or infliximab 5 mg/kg or 
10 mg/kg at weeks 0, 2 and 6 
(to week 18)
Absence of any
draining fistulas
or reduction ≥ 50%
in the number of
draining fistulas
at week 18
Adalimumab vs. placebo
[14] Hanauer
2006, 
CLASSIC I; RCT;
55 sites
Moderate-to-
severe Crohn’s
disease
Placebo, n = 74; adali-
mumab 40/20 mg, 
n = 74, 80/40 mg, 
n = 75, 160/80 mg, 
n = 76
Induction:
placebo or adalimumab: 40 mg/20 mg,
80 mg/40 mg or 160 mg/80 mg at week
0/2 (to week 4)
Remission: 
CDAI < 150
at week 4
[15] Sandborn
2007, GAIN;
RCT; 52 sites
Moderate-to-
severe Crohn’s
disease for 
≥ 4 months,
after previous
infliximab
Placebo, n = 166; 
adalimumab, n = 159
Induction:
placebo or adalimumab 160/80 mg 
at week 0/2 (to week 4)
Remission: 
CDAI < 150 at
week 4. Response:
decrease in CDAI
score of > 70 
or > 100 points 
at week 4
[16] Sandborn
2007, 
CLASSIC II;
RCT; 53 sites
As above; 
55 patients in
remission at
week 0 (week
4 of CLASSIC I)
Placebo, n = 18; adali-
mumab 40 mg every
other week, n = 19;
adalimumab 40 mg
weekly, n = 18
Maintenance:
initial adalimumab or placebo as part of
study CLASSIC-I, then remission after
open-label adalimumab 40 mg (week 0
(week 4 of CLASSIC I) and 2), then ran-
domization to placebo or adalimumab
40 mg weekly or 40 mg every other
week (to week 56)
Remission: 
CDAI ≤ 150 at 56
weeks. Response:
decrease in CDAI
score of > 70 or 
> 100 points at week
56 (from week 0
in CLASSIC I)
Table III. Characteristics of included studies
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Study author 
and year 
of publication;
design; sites
Population;
severity of CD
N (for efficacy) Dosage and schedule, duration 
of treatment and follow-up
Outcomes and
point at which
extracted
[17] Colombel
2007, CHARM;
RCT, 92 sites
Moderate-to-
severe, active
Crohn’s dis-
ease, also with
draining 
fistulas
Randomized respon-
ders: placebo, n = 170;
adalimumab 40 mg
every other week, 
n = 172; adalimumab
40 mg weekly, n = 157
with fistulas: placebo,
n = 47; adalimumab, 
n = 70
Maintenance:
initial response to open-label adalimum-
ab 80/40 mg (week 0/2); at week 4 ran-
domization to placebo or adalimumab
40 mg weekly or 40 mg every other
week (to week 56)
Remission: CDAI 
< 150 at weeks 
26 and 56 (for
responders).
Response:
decrease in CDAI
score of > 70 or 
> 100 points at
weeks 25 and 56.
Complete fistula
healing
[18] Rutgeerts
2012, EXTEND;
RCT; 19 sites
Moderate-to-
severe Crohn’s
disease for ≥ 4
months and
presence of
mucosal ulcer-
ation, also with
fistulas (12%)
Placebo, n = 65; 
adalimumab, n = 64
Maintenance:
initial response to open-label adalimum-
ab 160/80 mg at week 0/2; at week 4
randomization to placebo or adalimumab
40 mg every other week (to week 52).
Note: maintenance without preselection
for a response to induction but randomiza-
tion stratified by CR-70 status at week 4
Remission: 
CDAI < 150 at
weeks 12 and 52.
Response:
decrease in CDAI
score of > 70 or 
> 100 points at
weeks 12 and 52
[19] Watanabe
2012; RCT;
multicentre 
Moderate-to-
severe, active
Crohn’s dis-
ease for ≥ 4
months
Induction: placebo, 
n = 23; adalimumab
160/80 mg, n = 33;
80/40 mg, n = 34
Induction:
placebo or adalimumab 160/80 mg or
adalimumab 80/40 mg at week 0/2 
(to week 4)
Remission: CDAI 
< 150 at week 4.
Response: decrease
in CDAI score of 
> 70 or > 100 points
at week 2 and 4 (for
patients with remis-
sion at week 2)
Maintenance:
placebo, n = 25; adali-
mumab 40 mg, n = 25
Maintenance (responders only): 
at week 4 randomization to placebo 
or adalimumab 40 mg every other week
for 52 weeks
Remission: CDAI 
< 150 at week 52.
Response: as
above, at week 52
Certolizumab vs. placebo
[20] Winter
2004; RCT; 
24 sites
Moderate to
severe Crohn’s
disease
Placebo, n = 24; 
certolizumab 1.25 mg,
n = 2; 5 mg, n = 26; 
10 mg, n = 17; 
20 mg/kg, n = 23
Induction:
placebo or certolizumab 5 mg/kg; 10 mg
or 20 mg/kg at week 0 (followed to
week 12)
Remission: CDAI 
≤ 150 at week 4.
Response:
decrease in CDAI
score of ≥ 100
points at week 4
[21] Schreiber
2005; RCT; 
58 sites
Moderate to
severe Crohn’s
disease
Placebo, n = 73;
certolizumab 100 mg, 
n = 74; 200 mg, n = 72;
400 mg, n = 72
Induction:
placebo or certolizumab 100 mg, 
200 mg or 400 mg at week 0 and fur-
ther doses of the same medication at
weeks 4 and 8
Remission: CDAI 
≤ 150 at week 12.
Response:
decrease in CDAI
score of ≥ 100
points
[22] Sandborn
2011; RCT;
120 sites
Moderate to
severe Crohn’s
disease
Placebo, n = 209; 
certolizumab, n = 215
Induction:
placebo or certolizumab 400 mg at
weeks 0, 2, and 4 (followed to week 6)
Remission, CDAI 
≤ 150 at weeks 2,
4 and 6. Response:
decrease in CDAI
score of ≥ 100
points at weeks 2,
4 and 6
[23] Sandborn
2007, 
PRECiSE I; 
RCT; 171 sites
Moderate to
severe, active
Crohn’s dis-
ease for ≥ 3
months, also
with fistulas
Placebo, n = 328; 
certolizumab, n = 331
Short- and long-term induction: placebo
or certolizumab 400 mg at weeks 0, 2,
and 4 and then every 4 weeks 
(to week 26).
Note: treatment after week 4 without pre-
selection for a response to induction
Remission: CDAI 
≤ 150 at week 6
and 26. Response:
decrease in CDAI
score of ≥ 100 points
at week 6 and 26
(and combined)
Table III. Cont.
Arch Med Sci 5, October / 2013 771
Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
that this way of administering certolizumab did not
affect the results. The overall analysis revealed that
the anti-TNF therapy was significantly more effec-
tive than placebo for induction of remission at week
4 (RB = 1.90, 95% CI: 1.55–2.33, p < 0.00001). Results
of the analysis in subgroups have shown that the
probability of remission was significantly higher for
both adalimumab and certolizumab when com-
pared to the placebo (Figure 2). A subgroup analy-
sis could not be performed for infliximab because
only one study was available for this endpoint.
Maintenance of remission after open-label
induction
Seven trials that evaluated maintenance of inflix-
imab [10, 11], adalimumab [16–19] and certolizum-
ab [23, 24] were included in the evaluation of main-
tenance of remission among responders after
open-label induction (except for study [18] where
patients underwent maintenance treatment irre-
spective of the response to the previous induction
phase). In the overall analysis the anti-TNF thera-
py was significantly more effective than the place-
bo for the maintenance of remission at weeks 48–
56 (RB = 2.75, 95% CI: 2.13–3.54, p < 0.00001). In
the subgroup analysis there were also significant
benefits in favor of infliximab and adalimumab (Fig-
ure 3). The inclusion of the certolizumab results
from study [24] did not affect the overall efficacy of
the anti-TNF therapy for the maintenance of remis-
sion (RB = 2.30, 95% CI: 1.73–3.06, p < 0.00001). The
results of subgroups (infliximab vs. placebo RB =
2.00, 95% CI: 1.44–2.77, p < 0.0001; adalimumab vs.
placebo RB = 2.24, 95% CI: 1.69–2.98, p < 0.00001;
certolizumab vs. placebo RB = 1.64, 95% CI: 
1.36–1.99, p < 0.00001) and the results of the over-
all meta-analysis (RB = 1.86, 95% CI: 1.61–2.15, 
p < 0.00001) for the maintenance of remission at
weeks 20–30 (including study [23] with random-
ization before the induction) show that each of the
three anti-TNF agents was significantly more effec-
tive than the placebo.
Rates of fistula closure
Seven studies evaluated the anti-TNF agents for
the treatment of fistulizing CD, although only 2 of the
trials were designed specifically to address this issue
[12, 13]. During short-term induction treatment with
infliximab [13] and adalimumab [14, 15] significantly
more patients achieved a ≥ 50% reduction in fistulas
in comparison with the placebo (RB = 1.70, 95% CI:
1.03–2.82, p = 0.04). Similarly, in the long-term main-
tenance, both infliximab [12] and certolizumab [25]
were associated with significantly greater rates for 
≥ 50% fistula closure in the reported follow-up (RB =
1.84, 95% CI: 1.26–2.67, p = 0.001). When evaluating
complete fistula closure, we also took into account
the data from the short- and long-term induction tri-
Study author 
and year 
of publication;
design; sites
Population;
severity of CD
N (for efficacy) Dosage and schedule, duration 
of treatment and follow-up
Outcomes and
point at which
extracted
[24] Schreiber
2007, 
PRECiSE II;
RCT; 147 sites
Moderate to
severe, active
Crohn’s dis-
ease for ≥ 3
months
Placebo, n = 210; 
certolizumab, n = 215
Maintenance:
initial response to open label cer-
tolizumab at weeks 0, 2, and 4; at week
6 randomization to placebo or certolizu -
mab 400 mg every 4 weeks (to week 
24 and followed through week 26)
Remission: 
CDAI ≤ 150.
Response:
decrease in CDAI
score of ≥ 100
points at week 26
[25] Schreiber
2011, 
PRECiSE II
As above; 
subgroup of
patients with
draining fistu-
las at baseline
Placebo, n = 30; 
certolizumab, n = 28
At week 6, responders with draining 
fistulas (n = 58) were randomized to
placebo or certolizumab 400 mg every 
4 weeks across weeks 8–24
Absence of any
draining fistulas
at week 26
Infliximab vs. adalimumab
[26] Van Ass-
che 2012,
SWICH; RCT;
single-centre
Crohn’s dis-
ease and ongo-
ing response to
at least 6
months of
maintenance
infliximab
Infliximab, n = 37;
adalimumab, n = 36
Maintenance:
infliximab 5 mg/kg or adalimumab 
80 mg at baseline followed by 40 mg
every other week for 54 weeks
Dose intensifica-
tion, early treat-
ment termination,
preferences,
increase in the
CDAI of > 100
above baseline
[27] Riis 2012;
retrospective,
cohort study
Crohn’s 
disease
Infliximab, n = 64;
adalimumab, n = 19
Infliximab 5 mg/kg at weeks 0, 2 and 
6 or adalimumab 80 mg at baseline 
followed by 40 mg every other week 
(up to median 11.4 months)
Discontinuation of
anti-TNF therapy,
hospitalization
and surgery rates
Table III. Cont.
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al [23]. In the short-term induction therapy, combined
infliximab [13] and adalimumab [14, 15] were superi-
or to the placebo in the complete healing of fistulas
(RB = 2.44, 95% CI: 1.13–5.28, p = 0.02). Likewise, there
was a statistically significant benefit of combined
infliximab [12], adalimumab [17] and certolizumab [25]
over the placebo for complete fistula closure during
the maintenance treatment (RB = 2.03, 95% CI: 1.38–
2.98, p = 0.0003). No significant difference was detect-
ed in the rates of complete fistula healing in the
Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.1.1 Infliximab
Targan 1997 27 83 1 15 1.4% 4.88 (0.72, 33.24)
Subtotal (95% CI) 83 15 1.4% 4.88 (0.72, 33.24) 
Total events 27 1 
Heterogeneity: non applicable 
Test for overall effect: Z = 1.62 (p = 0.11) 
1.1.2 Adalimumab 
Hanauer 2006 CLASSIC I 58 225 9 74 10.9% 2.12 (1.11, 4.06)
Sandborn 2007 GAIN 34 159 12 166 9.4% 2.96 (1.59, 5.51)
Watanabe 2012 17 67 3 23 3.6% 1.95 (0.63, 6.04) 
Subtotal (95% Cl) 451 263 23.9% 2.42 (1.60, 3.63) 
Total events 109 24 
Heterogeneity: χ2 = 0.70, df = 2 (p = 0.70); I2 = 0% 
Test for overall effect: Z = 4.17 (p < 0.0001) 
1.1.3 Certolizumab 
Sandborn 2007 PRECISE I 63 331 36 328 29.1% 1.73 (1.19, 2.54) 
Sandborn 2011 57 215 40 209 32.6% 1.39 (0.97, 1.98) 
Schreiber 2005 46 219 6 73 7.2% 2.56 (1.14, 5.74)
Winter 2004 25 65 5 25 5.8% 1.92 (0.83, 4.46) 
Subtotal (95% Cl) 830 635 74.7% 1.63 (1.32, 2.13) 
Total events 191 87 
Heterogeneity: χ2 = 2.28, df = 3 (p = 0.52); I2 = 0% 
Test for overall effect: Z = 4.24 (p < 0.0001) 
Total (95% CI) 1364 913 100.0% 1.90 (1.55, 2.33) 
Total events 327 112 
Heterogeneity: χ2 = 6.74, df = 7 (p = 0.46); I2 = 0% 
Test for overall effect: Z = 6.10 (p < 0.00001) 
Test for subgroup differences: χ2 = 3.26, df = 2 (p = 0.20); I2 = 38.6%
0.01 0.1 1 10 100
Favours placebo       Favours anti-TNF
Figure 2. The effect of anti-TNF agents compared with placebo on induction of remission at week 4
Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.2.1 Infliximab 
Hanauer 2002 ACCENT I 75 225 15 110 27.9% 2.44 (1.47, 4.05)
Rutgeerts 1999 13 37 7 36 9.8% 1.81 (0.82, 4.01)
Subtotal (95% CI) 262 146 37.7% 2.28 (1.48, 3.50) 
Total events 88 22 
Heterogeneity: χ2 = 0.40, df = 1 (p = 0.53); I2 = 0% 
Test for overall effect: Z = 3. 76 (p = 0.0002) 
1.2.2 Adalimumab 
Colombel 2007 CHARM 126 329 20 170 36.5% 3.26 (2.11, 5.02) 
Rutgeerts 2012 21 64 6 65 8.2% 3.55 (1.54, 8.23)
Sandborn 2007 CLASSIC II 30 37 8 18 14.9% 1.82 (1.06, 3.13) 
Watanabe 2012 10 25 2 25 2.8% 5.00 (1.22, 20.55) 
Subtotal (95% CI) 455 278 62.3% 3.03 (2.21, 4.16) 
Total events 187 36 
Heterogeneity: χ2 = 4.13, df = 3 (p = 0.25); I2 = 27% 
Test for overall effect: Z = 6.87 (p < 0.00001) 
Total (95% CI) 717 424 100.0% 2.75 (2.13, 3.54) 
Total events 275 58 
Heterogeneity: χ2 = 5.12, df = 5 (p = 0.40); I2 = 2% 
Test for overall effect: Z = 7.80 (χ2 < 0.00001) 
Test for subgroup differences: χ2 = 1.10, df = 1 (p = 0.29); I2 = 9.2%
0.01 0.1 1 10 100
Favours placebo       Favours anti-TNF
Figure 3. The effect of anti-TNF agents compared with placebo on maintenance of  remission at week 48–56 (exclud-
ing study [24])
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short- and long-term induction trial [23] (RB = 1.02,
95% CI: 0.58–1.82, p = 0.94) (Figure 4).
Induction of response (70-CR and 100-CR) 
at week 4
Data on the clinical response rate defined as 
70-CR or 100-CR in the CDAI score at week 4 of
short- and long-term induction trials were available
and extracted from seven studies (one evaluating
infliximab [9] and three for both adalimumab [14,
15, 19] and certolizumab [20, 22, 23]). In the overall
analysis the anti-TNF therapy was more effective
than the placebo for achieving the clinical response
described as 70-CR at week 4 (RBfixed = 1.64, 
95% CI: 1.37–1.95, p < 0.00001). The subgroup analy-
sis also favored infliximab and adalimumab but not
the certolizumab used in the single eligible study
[23]. Data on the clinical response 100-CR at week
4 of the induction treatment was available in six tri-
als. There were no data on infliximab and 100-CR
at week 4. In the subgroup and overall analysis,
there were no statistically significant differences
between anti-TNF agents, both adalimumab and
certolizumab versus placebo (RB = 1.21, 95% CI:
0.81–1.80, p = 0.35) (Figure 5).
Clinical response (70-CR and 100-CR) during
maintenance
Five trials evaluated the clinical response defined as
70-CR during the long-term maintenance treatment
with infliximab [10, 11] and adalimumab [16–18]. There
were no extractable data for certolizumab. The overall
result of the meta-analysis demonstrated that the
anti-TNF therapy was statistically beneficial when
compared to the placebo in achieving 70-CR at weeks
48–56 (RBrandom = 2.06, 95% CI: 1.32–3.23, p = 0.002).
To assess the 100-CR rates, there were no data
regarding infliximab, although a study evaluating cer-
tolizumab at week 26 was included [24]. The anti-TNF
therapy was associated with a significantly increased
relative benefit of achieving response 100-CR during
maintenance when compared to the placebo (RB =
2.03, 95% CI: 1.48–2.78, p < 0.0001) (Figure 6). Exclud-
ing study [24], in which the data were extracted at
week 26, the final result remains statistically unaf-
fected (RB = 2.21, 95% CI: 1.40–3.51, p < 0.0001).
The outcomes evaluated in 2 studies comparing
infliximab and adalimumab with each other were
different from those concerning placebo-controlled
trials. In study [26] the results for adalimumab ther-
apy (after switching from infliximab) were statisti-
cally inferior when compared to the continued 
use of infliximab with regard to the need for dose
intensification, risk of early treatment termination
(RR = 0.34, 95% CI: 0.15–0.77, p = 0.01) and risk of
treatment discontinuation due to loss of response
or intolerance (RR = 0.10, 95% CI: 0.01–0.72, 
p = 0.02). Both important and inconsistent with the
clinical results, significantly more patients preferred
adalimumab over infliximab at most time points
throughout the study. In the cohort study [27] most
Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.5.1 Fistula closure in short-term induction 
Hanauer 2006 CLASSIC I 3 26 1 6 2.9% 0.69 (0.09, 5.55)
Present 1999 29 63 4 31 9.7% 3.57 (1.38, 9.25) 
Sandborn 2007 GAIN 1 20 2 25 3.2% 0.63 (0.06, 6.41)
Subtotal (95% CI) 109 62 15.8% 2.44 (1.13, 5.28)
Total events 33 7 
Heterogeneity: χ2 = 3.33, df = 2 (p = 0.19); I2 = 40% 
Test for overall effect: Z = 2.26 (p = 0.02) 
1.5.2 Fistula closure in maintenance after open-label induction 
Colombel 2007 CHARM 23 70 6 47 12.9% 2.57 (1.13, 5.84) 
Sands 2004 ACCENT II 33 96 19 99 33.7% 1.79 (1.10, 2.92) 
Schreiber 2011 PRECISE II 10 28 5 30 8.7% 2.14 (0.84, 5.50) 
Subtotal (95% CI) 194 176 55.4% 2.03 (1.38, 2.98) 
Total events 66 30 
Heterogeneity: χ2 = 0.59, df = 2 (p = 0.75); I2 = 0% 
Test for overall effect: Z = 3.60 (p = 0.0003) 
1.5.3 Fistula closure in short and long-term induction 
Sandborn 2007 PRECISE I 19 61 14 46 28.8% 1.02 (0.58, 1.82)
Subtotal (95% CI) 61 46 28.8% 1.02 (0.58, 1.82)
Total events 19 14 
Heterogeneity: not applicable 
Test for overall effect: Z = 0.08 (p = 0.94) 
Total (95% CI) 364 284 100.0% 1.80 (1.34, 2.42) 
Total events 118 51 
Heterogeneity: χ2 = 8.17, df = 6 (p = 0.23); I2 = 27% 
Test for overall effect: Z = 3.93 (p < 0.0001) 
Test for subgroup differences: χ2 = 4.62, df = 2 (p = 0.10); I2 = 56.7%
0.01 0.1 1 10 100
Favours (experimental)       Favours (control)
Figure 4. The effect of anti-TNF agents compared with placebo on complete fistula closure
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of the presented results concerned combined data
for infliximab and adalimumab but, contrary to
study [26], no statistically significant difference was
detected between infliximab and adalimumab in
the need for dose intensification (RR = 3.28, 
95% CI: 0.45–23.95, p = 0.24).
Safety analysis
We analyzed the incidence of any adverse events
(AEs) and serious adverse events (SAEs) both occur-
ring as a result of the short-term induction thera-
py and separately, and incidence of AEs during the
long-term maintenance, irrespective of the pres-
ence of fistula.
All adverse events or serious adverse events
during short-term induction therapy
In the overall analysis, there was no significant
difference in the frequency of any AEs between
anti-TNF therapy and the placebo (RR = 1.00, 
Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.7.2 Adalimumab 
Hanauer 2006 CLASSIC I 93 225 19 74 17.6% 1.61 (1.06, 2.44)
Sandborn 2007 GAIN 61 159 41 66 19.8% 0.62 (0.47, 0.81)
Watanabe 2012 32 67 4 23 10.0% 2.75 (1.09, 6.93)
Subtotal (95% Cl) 451 163 47.3% 1.31 (0.53, 3.24) 
Total events 186 64 
Heterogeneity: τ2 = 0.56; χ2 = 23.04, df = 2 (p < 0.00001); I2 = 91% 
Test for overall effect: Z = 0.58 (p = 0.56) 
1.7.3 Certolizumab 
Sandborn 2007 PRECISE I 28 331 21 328 15.5% 1.32 (0.77, 2.28) 
Sandborn 2011 76 215 55 209 19.5% 1.34 (1.01, 1.80)
Winter 2004 36 65 14 25 17.7% 0.99 (0.66, 1.49)
Subtotal (95% CI) 611 562 52.7% 123 (0.99, 1.53)
Total events 140 90 
Heterogeneity: τ2 = 0.00; χ2 = 1.57, df = 2 (p = 0.46); I2 = 0% 
Test for overall effect: Z = 1.86 (p = 0.06) 
Total (95% CI) 1062 725 100.0% 121 (0.81, 1.80) 
Total events 326 154 
Heterogeneity: τ2 = 0.19; χ2 = 28.18, df = 5 (p < 0.0001); I2 = 82% 
Test for overall effect: Z = 0.93 (p = 0.35) 
Test for subgroup differences: χ2 = 0.02, df = 1 (p = 0.90); I2 = 0% 0.01 0.1 1 10 100
Favours placebo       Favours anti-TNF
Figure 5. The effect of anti-TNF agents compared with placebo on clinical response at week 4; 100 – CR
Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.9.1 Adalimumab 
Colombel 2007 CHARM 146 329 28 179 27.1% 2.84 (1.98, 4.07)
Rutgeerts 2012 23 64 9 65 13.9% 2.60 (1.30, 5.17)
Sandborn 2007 CLASSIC II 31 37 10 18 23.3% 1.51 (0.97, 2.33)
Subtotal (95% Cl) 430 262 64.3% 2.21 (1.40, 3.51) 
Total events 200 47 
Heterogeneity: τ2 = 0.10; χ2 = 5.60, df = 2 (p < 0.06); I2 = 64% 
Test for overall effect: Z = 3.38 (p = 0.0007) 
1.9.2 Certolizumab 
Schreiber 2007 PRECISE II 135 215 76 210 35.7% 1.74 (1.41, 2.13)
Subtotal (95% CI) 215 210 35.7% 1.74 (1.41, 2.13)
Total events 135 76 
Heterogeneity: Not applicable 
Test for overall effect: Z = 5.22 (p < 0.00001) 
Total (95% CI) 645 472 100.0% 2.03 (1.48, 2.78) 
Total events 335 123 
Heterogeneity: τ2 = 0.06; χ2 = 8.09, df = 3 (p < 0.04); I2 = 63% 
Test for overall effect: Z = 4.42 (p < 0.0001) 
Test for subgroup differences: χ2 = 0.89, df = 1 (p = 0.34); I2 = 0%
0.01 0.1 1 10 100
Favours placebo       Favours anti-TNF
Figure 6. The effect of anti-TNF agents compared with placebo on clinical response during maintenance; 100 – CR
(including study [24])
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95% CI: 0.90–1.12, p = 0.97) in the short-term induc-
tion treatment (range: 4–12 weeks [9, 13–15, 19–22]).
In the subgroup analysis, the differences between
the anti-TNF agents and placebo were not signifi-
cant either (infliximab vs. placebo RR = 1.19, 95%
CI: 0.95–1.49, p = 0.12; adalimumab vs. placebo RR
= 0.88, 95% CI: 0.75–1.03, p = 0.11; certolizumab
vs. placebo RR = 1.06, 95% CI: 0.94–1.20, p = 0.32).
The results of study [23] were excluded from the
abovementioned analysis because the follow-up
time was up to 26 weeks, although in the end the
inclusion of its results did not affect the overall
effect (RRfixed =1.00, 95% CI: 0.95–1.06, p = 0.91).
The pooled relative risk of the occurrence of SAEs
(Figure 7) during the short-term induction treat-
ment (4–12 weeks [15, 19–22], study [23] excluded)
indicated the lack of statistical difference between
therapies with anti-TNF agents and the placebo 
(RR = 1.00, 95% CI: 0.62–1.63, p = 0.99). There were
no data available for infliximab on this outcome.
After the inclusion of study [23] the risk was 1.20
(95% CI: 0.85–1.71, p = 0.30).
All adverse events or serious adverse events
during long-term maintenance therapy
No statistically significant difference in the inci-
dence of any AEs during the long-term maintenance
therapy (48–56 weeks for [10, 12, 16–19], 26 weeks
for the PRECISE II study [24]) was detected with the
anti-TNF agents when compared with the placebo
(RR = 0.99, 95% CI: 0.93–1.05, p = 0.72). The over-
all result of the meta-analysis revealed a statisti-
cally significant difference in the frequency of SAEs
during the maintenance therapy in favor of the anti-
TNF agents over the placebo (RR = 0.70, 95% CI:
0.58–0.86, p = 0.0005) [11, 12, 16–19, 24], mainly
due to a significantly lower risk of SAEs in the sub-
group analysis for adalimumab [16–19] (Figure 8).
Using the data available from study [26] as a basis,
there was no statistically significant difference
detected in the risk of any AEs related to the anti-
TNF therapy with infliximab when compared to
adalimumab (RR = 0.88, 95% CI: 0.69–1.12, p = 0.29).
Discussion
According to our knowledge, this is the first
meta-analysis of the anti-TNF therapy in moderate
to severe CD, involving fistulizing patients, that
includes infliximab, adalimumab and certolizumab.
Both infliximab and adalimumab are indicated
for moderate to severe CD in patients unresponsive
to or intolerant of conventional treatments. Al -
though certolizumab has also shown promising
data in adults with CD and received approval from
the US FDA, it has not yet been approved by the
EMA for that indication.
There were a few limitations for this meta-analy-
sis. First, there are differences in design between
the included studies: various periods of treatment
with different aims (induction, maintenance), using
different doses of agents given at various intervals
throughout the studies and irrespective of the con-
comitant therapy. It is important to note that we
performed a meta-analysis for the different types
of study design separately: short-term induction tri-
als with randomization before induction, long-term
maintenance trials with randomization of respond-
ing patients at weeks 2–6 after open-label induc-
tion treatment, and one long-term induction trial
with randomization before induction. The same
method was used for evaluating the effect of the
Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.11.1 Adalimumab 
Sandborn 2007 GAIN 2 159 8 166 25.3% 0.26 (0.06, 1.21) 
Watanabe 2012 4 67 2 23 9.6% 0.69 (0.13, 3.50) 
Subtotal (95% CI) 226 189 35.0% 0.38 (0.13, 1.14) 
Total events 6 10 
Heterogeneity: χ2 = 0.74, df = 1 (p = 0.39); I2= 0% 
Test for overall effect: Z = 1.73 (p = 0.08) 
1.11.2 Celtolizumab 
Sandborn 2011 12 223 8 215 26.4% 1.45 (0.60, 3.47) 
Schreiber 2005 23 219 6 73 29.1% 1.28 (0.54, 3.02) 
Winter 2004 7 68 2 24 9.6% 1.24 (0.28, 5.54) 
Subtotal (95% CI) 510 312 65.0% 1.34 (0.76, 2.36)
Total events 42 16 
Heterogeneity: χ2 = 0.05, df = 2 (p = 0.97); I2 = 0% 
Test for overall effect: Z = 1.01 (p = 0.31) 
Total (95% CI) 736 501 100.0% 1.00 (0.62, 1.63)
Total events 48 26 
Heterogeneity: χ2 = 4.22, df = 4 (p = 0.38); I2 = 5% 
Test for overall effect: Z = 0.01 (p = 0.99) 
Test for subgroup differences: χ2 = 3.99, df = 1 (p = 0.05); I2 = 74.9% 
0.01 0.1 1 10 100
Favours anti-TNF       Favours placebo
Figure 7. The effect of anti-TNF agents compared with placebo on risk of serious adverse events during induction
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anti-TNF agent on fistula healing. Due to the
methodological procedure, the limitations, con-
nected with the dissimilar design of the included
studies and their duration, did not influence the reli-
ability of the obtained results to a great extent.
Both short- and long-term induction studies were
used to evaluate clinical remission and response
rates at week 4 (for all the induction trials these
data were extractable, although some studies last-
ed up to 12 weeks). For the long-term maintenance
studies, the follow-up periods varied between 48 and
56 weeks, with one study lasting only 26 weeks
[24], and the last point of the trial follow-up was
used to extract the outcomes of the data wherev-
er trial reporting allowed it (likewise for the safety
analysis in both the induction and maintenance
therapy). In this setting, we carried out an additional
analysis based on extractable data on the mainte-
nance of remission at 20–30 weeks, with regard to
the study PRECISE II [24]. Apart from pooling the
results from studies of different anti-TNF agents,
different doses and slightly different durations of
therapy (except for the clinical outcomes at week
4), we performed subgroup analyses for each of the
anti-TNF agents in order to investigate potential
differences in their efficacy. The results of the main-
tenance trials were almost exclusively based on the
subgroups of the ‘responders’, which were select-
ed for the analysis or randomization at varying time
points after an induction period, during which all
the patients received the study drug. Separate
results for non-responders are not reported here.
What should be noted, including study [18] for the
maintenance of remission after open-label induction
could bias the overall results, because for this effi-
cacy endpoint we included studies evaluating the
maintenance of remission among responders after
open-label induction, while maintenance treatment
in study [18] was conducted among patients prob-
ably not strictly preselected for a response to induc-
tion treatment. Additionally, the meta-analysis
included the GAIN study [15], where adalimumab
was given to patients who did not achieve a res -
ponse to previous infliximab therapy, thus possibly
leading to an underestimation of the real efficacy
of the anti-TNF agents in this setting. In regards to
evaluation of the treatment effects on fistula heal-
ing, except data from two trials designed specifi-
cally to address this issue [12, 13], we extracted well-
defined data on fistula closure from other primary
studies also including patients with fistulizing dis-
ease, but it should be noted that patients included
in the studies [12, 13] have more severe CD com-
pared to all other studies included in this compar-
ison, in which patients had moderately to severely
active CD, defined as a CDAI score between 220 and
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Study or subgroup Anti-TNF Placebo Weight Risk ratio Risk ratio 
Events Total Events Total
M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.13.1 Infliximab 
Hanauer 2002 ACCENT I 97 385 55 188 39.5% 0.86 (0.65, 1.14)
Sands 2004 ACCENT II 19 138 33 144 17.3% 0.60 (0.36, 1.00) 
Subtotal (95% CI) 523 332 56.7% 0.78 (0.61, 1.00)
Total events 116 88 
Heterogenety: χ2 = 1.46, df = 1 (p = 0.23); I2 = 32% 
Test for overall effect: Z = 1.95 (p = 0.05) 
1.13.2 Adalimumab 
Colombe1 2007 CHARM 45 517 40 261 28.4% 0.57 (0.38, 0.85)
Rutgeerts 2012 4 64 5 65 2.7% 0.81 (0.23, 2.89) 
Sandborn 2007 CLASSIC II 1 37 2 18 1.4% 0.24 (0.02, 2.51) 
Watanabe 2012 2 25 6 25 3.2% 0.33 (0.07, 1.50) 
Subtotal (95% CI) 643 369 35.7% 0.55 (0.38, 0.79) 
Total events 52 53 
Heterogeneity: χ2 = 1.28, df = 3 (p = 0.73); I2 = 0% 
Test for overall effect: Z = 3.21 (p = 0.001) 
1.13.3 Certolizumab 
Schreiber 2007 PRECISE II 12 216 14 212 7.6% 0.84 (0.40, 1.78) 
Subtotal (95% CI) 216 212 7.6% 0.84 (0.40, 1.78) 
Total events 12 14 
Heterogeneity: not applicable 
Test for overall effect: Z = 0.45 (p = 0.65) 
Total (95% CI) 1382 913 100.0% 0.70 (0.58, 0.86) 
Total events 180 155 
Heterogeneity: χ2 = 5.47, df = 6 (p = 0.49); I2 = 0% 
Test for overall effect: Z = 3.49 (p = 0.0005) 
Test for subgroup differences: χ2 = 2.64, df = 2 (p = 0.27); I2 = 24.1% 0.01 0.1 1 10 100
Favours anti-TNF       Favours placebo
Figure 8. The effect of anti-TNF agents compared with placebo on risk of serious adverse events durning mainte-
nance
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450. What is important, individual results from stud-
ies designed with healing of fistulas as the primary
outcome of interest demonstrated a clear, statisti-
cally significant benefit of infliximab as well as adal-
imumab over placebo, even in more severe disease
[12, 13]. Nevertheless, even after taking into con-
sideration the results of this particular study there
should be no difference in the reliability and sta-
tistical significance of the final results of the meta-
analysis.
We identified two studies regarding a head-to-
head comparison between infliximab and adali-
mumab [26, 27] in treatment for CD, but taking into
consideration the differences in their methodology
and quality, pooling the results was not recom-
mended and a narrative synthesis was performed
instead. 
Several meta-analyses have shown the efficacy
of anti-TNF therapy for inducing and maintaining
clinical response and remission in patients with CD.
It is a fact that these meta-analyses and reviews
were performed with less contemporaneous re -
search data and did not therefore consider the most
recent studies published in 2011 and 2012. Peyrin-
-Biroulet et al. [28] performed a meta-analysis com-
paring the effectiveness of six anti-TNF agents
(infliximab, adalimumab, certolizumab, etanercept,
onercept, and CDP571) with a placebo for induction
and maintenance, steroid-sparing and fistula clo-
sure in CD. The methods of conducting that analy-
sis were similar to ours. Based on 21 trials of which
16 were included in the efficacy analysis, there was
evidence that the anti-TNF therapy is effective in
patients with CD refractory to standard medical
therapy, but the authors stated that the efficacy of
the anti-TNF agents besides infliximab in the treat-
ment of fistulizing patients requires additional
investigation. Safety analyses revealed that the anti-
TNF therapy does not increase the risk of death,
serious infection or malignancy. However, subgroup
analyses were performed, and the results of the
overall meta-analysis also contain particular data
from studies evaluating an anti-TNF agent other
than antibodies (etanercept or onercept). The
results of review [29] showed the superiority of
infliximab, adalimumab and certolizumab (sepa-
rately) in relation to the placebo for the mainte-
nance of remission in patients who have respond-
ed to prior induction therapy, but only infliximab
was effective for the maintenance of fistula heal-
ing. The review also has two drawbacks. Firstly, it
encompasses a small number of studies: three con-
cerning infliximab, then two and one examining
adalimumab and certolizumab, respectively. Sec-
ondly, the pooled results consisted of data from no
more than two studies. This was caused by the fact
that no overall (all anti-TNF agents combined) meta-
analysis was performed. Results from 11 trials
included in a more recent systematic review [30]
showed that both infliximab and adalimumab were
beneficial for induction and maintenance therapy
in adults with moderate to severe CD, and inflix-
imab only for adults with a fistula when compared
to a placebo. Certolizumab was not assessed. It also
needs to be highlighted that the data from studies
included in review [30] were not pooled in the meta-
analysis, and, for that reason, the conclusion from
that descriptive analysis should be interpreted cau-
tiously. In review [31] there is an assessment of bio-
logical therapies (three anti-TNF antibodies and
anti-integrin antibody) for Crohn’s disease and
ulcerative colitis (UC) treatment. In the overall
analysis, the anti-TNF agents (certolizumab, adali-
mumab, and infliximab combined) were signifi-
cantly more effective than the placebo for inducing
remission and preventing relapse of CD, although
the pooled data from six studies demonstrated no
statistically significant difference in regard to heal-
ing of fistulizing CD. In review [31], as described in
the data extraction methodology, the data con-
cerning the outcomes were extracted at the last
point of the trial follow-up. It means that, as
opposed to our analysis, the data for the induction
of remission were extracted at different time points
due to the fact that the eligible time of outcome
assessment for induction trials was up to 4 months
(note that induction therapy in study [23] lasted 
26 weeks). In addition, the combined result for fistu-
la healing was presented without explanation of its
definition (complete or partial closure). Our results
on induction of remission or clinical response at
week 4 are contrary to results obtained in the meta-
analysis by Rahimi et al., 2011 [32]. That meta-analy-
sis included studies in which patients with CD were
exposed to any therapeutic dosage of any anti-TNF
agents (infliximab, certolizumab, CDP870, CDP571,
etanercept, onercept) and shared some trials includ-
ed in the current analysis. The results demonstrat-
ed that anti-TNF agents have no statistically sig-
nificant effects on induction of remission after 
2 weeks of treatment as well as clinical response and
remission after 4 weeks. The only statistically sig-
nificant benefit of anti-TNF agents over the place-
bo was observed for improving clinical response
after 2 weeks of treatment. What is important, rel-
evant data included in meta-analysis [32] were col-
lected up to December 2005. On the other hand,
results from a meta-analysis including studies con-
cerning severe ulcerative colitis [33] showed that
infliximab was significantly more beneficial than
placebo for induction of remission at 2–8 weeks and
slightly, but not significantly better than corticos-
teroids in regards to the induction of clinical remis-
sion up to week 13. 
Fistulas, one of the most severe complications
of CD, causes impairment in the quality of life and
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increase the likelihood of total colectomy. Perianal
fistula is the most common fistula type, occurring
in 25–50% of patients with CD [12, 25]. As men-
tioned above, some meta-analyses of anti-TNF anti-
bodies have shown success with their use in fis-
tulizing CD, but it particularly concerns infliximab
[28–30]. Apart from surgery, another method of fis-
tula treatment is short-term therapy with antibi-
otics. In a review [34] pooling of data showed that
immunoregulators and antibiotics are significantly
more effective than placebo for ≥ 50% as well as
complete fistula closure in fistulizing CD. In recent
years treatment with anti-TNF antibodies has sig-
nificantly improved the management of CD as well
as UC refractory to conventional therapies; never-
theless, there is still a large number of patients
showing an evaluative and disabling course of dis-
ease who require surgery [3]. Pre-operative use of
biological therapy such as anti-TNF agents may
potentially increase the risk for postoperative infec-
tious complications by suppression of the immune
response. In the meta-analysis performed by Ehte-
shami-Afshar et al., 2011 [2], there was no evidence
of significant differences in the rate of colectomy,
post-colectomy infectious complications or deaths
in patients with ulcerative colitis who received
infliximab in comparison to those who did not. After
pooling results from studies assessing UC and CD,
the overall early post-operative complications were
more frequent among patients who received inflix-
imab pre-operatively (but not late post-operative
complications). Nonetheless, the rate of post-oper-
ative hospitalization was significantly lower in pa -
tients with UC under infliximab therapy [2].
Overall, anti-TNF therapy is a relatively safe treat-
ment option in CD and other inflammatory bowel
diseases [1]. Results of our meta-analyses demon-
strated no significant differences in the frequency
of any adverse events, including serious AEs,
between anti-TNF therapy and placebo during short-
term treatment. Moreover, there was a significant-
ly lower risk of SAEs during maintenance therapy
in favor of anti-TNF agents over placebo. 
The overall results of our meta-analysis indicat-
ed consistent superiority of the anti-TNF antibod-
ies when compared to placebo in the induction and
maintenance of clinical remission, but notably, in
contrast to reviews [28, 31], we demonstrated their
significant beneficial effect on fistula healing also
in short-term induction therapy. What should be
emphasized is that we took into consideration such
outcomes as clinical response (CR-70, CR-100),
which was evaluated separately for both short-term
induction and maintenance therapy, and has not
been meta-analyzed in any previous reviews, except
for article [29], where the attention was only on
maintenance therapy in patients who had already
had remission after induction therapy, and article
[32] concerning the short-term induction phase. In
contrast to previous articles, our updated review
mentions the newest studies evaluating two of the
anti-TNF antibodies in comparison with each other.
With respect to previous review studies, our sys-
tematic review is the most up-to-date systematic
review (including studies published in 2012) on the
effect of anti-TNF antibodies in CD, which in its
methodology followed the methods described in
the Cochrane Handbook, with the report having
been prepared according to the PRISMA statement.
In conclusion, in general, the results of the meta-
analysis demonstrated that anti-TNF therapy has
a beneficial effect on induction and maintenance
of clinical remission and response, as well as fistu-
la healing, when compared with placebo. Based on
a safety analysis, there was no evidence for an
increase in the incidence of any adverse events
related to anti-TNF when compared with placebo.
In conclusion, the risk-benefit ratio of therapy with
infliximab, adalimumab or certolizumab in CD is
therefore in favor of these agents.
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